[5] Three- month BCR-ABL IS levels of less than 10% are predictive of long-term outcomes in CML including higher rates of MMR and MR 4.5, and a rapid initial decline in BCR-ABL IS levels also correlate with subsequent achievement of treatment free remission [4, 14]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.